IP Library Granted Patent US 11,364,258
Granted Patent B2
US 11,364,258 · App. 16/082,222 · Granted Jun 21, 2022

Methods for treating chondrosarcoma using microrna(miR)

Inventors: Richard Terek (Providence, RI); Qian Chen (Barrington, RI); Xiaojuan Sun (Barrington, RI)
Assignee: Rhode Island Hospital
A61K31/7105A61K9/5184A61K31/395C12N15/113A61K9/0019A61K45/06C12N2310/113
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,364,258
App. No.
16/082,222
Granted
Jun 21, 2022
Kind
B2
Abstract

This invention is directed to, inter alia, compositions and methods for restoring normal microRNA (miR) expression in chondrosarcoma cells as well as methods for treating and diagnosing chondrosarcoma in individuals in need thereof.

Claims (9)

1. A method for treating chondrosarcoma in an individual in need thereof, the method comprising identifying an individual diagnosed with chondrosarcoma or a predisposition thereto and administering to the individual a therapeutically effective amount of one or more chondrosarcoma-inhibiting microRNA (miR), wherein the miR comprises miR-34a, wherein said method results in decreased expression of vascular endothelial growth factor (VEGF), synovial sarcoma X-1 (SSX1), and tyrosine-protein kinase Met (Met), and wherein said method results in decreased chondrosarcoma cellular proliferation, invasion, or metastasis.

2. The method of claim 1 , further comprising administering a chemotherapeutic to the individual.

3. The method of claim 2 , wherein said chemotherapeutic is AMD3100.

4. The method of claim 1 , further comprising administering an inhibitor of miR-181a.

5. The method of claim 1 , wherein the individual is diagnosed with conventional chondrosarcoma, periosteal chondrosarcoma, mesenchymal chondrosarcoma, dedifferentiated chondrosarcoma, clear-cell chondrosarcoma, or extraskeletal myxoid chondrosarcoma.

6. The method of claim 1 , wherein the method further comprises administration of one or more additional anti-cancer therapies to the individual.

7. The method of claim 6 , wherein said one or more additional anti-cancer therapies is surgical ablation of the chondrosarcoma.

8. The method of claim 1 , wherein the miR is administered by a nanopiece comprising a length of about 100 nm and width/diameter of about 20 nm.

9. The method of claim 1 , wherein the chondrosarcoma-inhibiting microRNA (miR) is administered to a tumor bed of the chondrosarcoma in the individual following surgical resection of a tumor.

Assignments (2)
CONFIRMATORY LICENSE Recorded May 4, 2020
From: RHODE ISLAND HOSPITAL
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 052558/0967 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 22, 2018
From: TEREK, RICHARD; CHEN, QIAN; SUN, XIAOJUAN
To: RHODE ISLAND HOSPITAL
Reel/Frame 047256/0061 →
Continuity (2)
Provisional Application 62304048 · Mar 4, 2016
Related Publication 20200289542A1 · Sep 17, 2020